Cargando…

PCSK9 and triglyceride-rich lipoprotein metabolism

Pro-protein convertase subtilisin-kexin 9 (PCSK9) is known to affect low-density lipoprotein (LDL) metabolism, but there are indications from several lines of research that it may also influence the metabolism of other lipoproteins, especially triglyceride-rich lipoproteins (TRL). This review summar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Druce, Irena, Abujrad, Hussein, Ooi, Teik Chye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Department of Journal of Biomedical Research 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662203/ https://www.ncbi.nlm.nih.gov/pubmed/26320603 http://dx.doi.org/10.7555/JBR.29.20150052

Ejemplares similares

Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood
por: Peticca, Patricia, et al.
Publicado: (2013)

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
por: Chan, Dick C., et al.
Publicado: (2018)

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
por: Mayne, Janice, et al.
Publicado: (2013)

Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia
por: Sun, Cathy J, et al.
Publicado: (2019)

Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
por: Gugliucci, Alejandro
Publicado: (2023)

Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
por: Zhang, Bai-Hui, et al.
Publicado: (2022)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
por: Mayne, Janice, et al.
Publicado: (2008)

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
por: Goonewardena, Sascha N., et al.
Publicado: (2023)

Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
por: Baratta, Francesco, et al.
Publicado: (2023)

Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease
por: Heo, Ji Hye, et al.
Publicado: (2023)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Effect of hemodialysis on extracellular vesicles and circulating submicron particles
por: Ruzicka, Marcel, et al.
Publicado: (2019)

A simplified procedure to trace triglyceride‐rich lipoprotein metabolism in vivo
por: Ying, Zhixiong, et al.
Publicado: (2021)

Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
por: Toth, Peter P
Publicado: (2016)

Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
por: Reiner, Željko
Publicado: (2018)

Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans
por: Adiels, Martin, et al.
Publicado: (2015)

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
por: Borén, Jan, et al.
Publicado: (2020)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
por: Dallinga-Thie, Geesje M., et al.
Publicado: (2016)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Triglyceride-rich lipoproteins prevent septic death in rats
Publicado: (1995)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism
por: Deprince, Audrey, et al.
Publicado: (2023)

Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review
por: Sascău, Radu, et al.
Publicado: (2021)

Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population
por: Hamamura, Hitoshi, et al.
Publicado: (2021)

Endothelial lipase mediates efficient lipolysis of triglyceride-rich lipoproteins
por: Khetarpal, Sumeet A., et al.
Publicado: (2021)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy
por: Srivastava, Anand, et al.
Publicado: (2016)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Delayed clearance of triglyceride‐rich lipoproteins in young, healthy obese subjects
por: Larsen, M. A., et al.
Publicado: (2015)

Correlation of Triglyceride-Rich Lipoprotein Cholesterol and Diabetes Mellitus in Stroke Patients
por: Luo, Ruiqing, et al.
Publicado: (2022)

Role of Altered Metabolism of Triglyceride-Rich Lipoprotein Particles in the Development of Vascular Dysfunction in Systemic Lupus Erythematosus
por: Diószegi, Ágnes, et al.
Publicado: (2023)

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
por: Li, Tingting, et al.
Publicado: (2021)

Beyond LDL: Understanding Triglyceride-Rich Lipoproteins to Tackle Residual Risk
por: Gugliucci, Alejandro
Publicado: (2023)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

PCSK9 targets important for lipid metabolism
por: Schulz, Rainer, et al.
Publicado: (2017)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f9mspq48kne7rk522n00mhksai